Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles S Galindo-Feria

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
JAMA|June 27, 2023
CD19-Targeting CAR T-Cell Therapy for Antisynthetase SyndromeIngrid E Lundberg, Angeles S Galindo-Feria, Begum Horuluoglu
Best Practice & Research. Clinical Rheumatology|July 9, 2022
Autoantibodies: Pathogenic or epiphenomenonAngeles S Galindo-Feria, Guochun Wang, Ingrid E Lundberg
Frontiers in Immunology|May 31, 2022
Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and BeyondAngeles S Galindo-Feria, Antonella Notarnicola, Ingrid E Lundberg, et al.
Rheumatology (Oxford, England)|May 17, 2022
ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositisSandra Selickaja, Angeles S Galindo-Feria, Lara Dani, et al.
Rheumatology (Oxford, England)|January 13, 2022
Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohortAngeles S Galindo-Feria, Begum Horuluoglu, Jessica Day, et al.
Neuromuscular Disorders : NMD|June 18, 2019
Concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody with reducing body myopathy: Possible double troubleJantima Tanboon, Oranee Sanmaneechai, Sirirat Charuvanij, et al.
Rheumatology (Oxford, England)|June 4, 2024
Anti-FHL1 autoantibodies in adult patients with myositis: a longitudinal follow-up analysisAngeles S Galindo-Feria, Karin Lodin, Begum Horuluoglu, et al.
Clinical & Developmental Immunology|October 27, 2011
Polymerized-type I collagen induces upregulation of Foxp3-expressing CD4 regulatory T cells and downregulation of IL-17-producing CD4⁺ T cells (Th17) cells in collagen-induced arthritisJanette Furuzawa-Carballeda, Perla Macip-Rodríguez, Angeles S Galindo-Feria, et al.
Arthritis Research & Therapy|March 3, 2022
Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndromeAntonella Notarnicola, Charlotta Preger, Susanna L Lundström, et al.
Arthritis Research & Therapy|December 2, 2024
Correction: Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndromeAntonella Notarnicola, Charlotta Preger, Susanna L Lundström, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
JAMA|June 27, 2023
CD19-Targeting CAR T-Cell Therapy for Antisynthetase SyndromeIngrid E Lundberg, Angeles S Galindo-Feria, Begum Horuluoglu
Best Practice & Research. Clinical Rheumatology|July 9, 2022
Autoantibodies: Pathogenic or epiphenomenonAngeles S Galindo-Feria, Guochun Wang, Ingrid E Lundberg
Frontiers in Immunology|May 31, 2022
Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and BeyondAngeles S Galindo-Feria, Antonella Notarnicola, Ingrid E Lundberg, et al.
Rheumatology (Oxford, England)|May 17, 2022
ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositisSandra Selickaja, Angeles S Galindo-Feria, Lara Dani, et al.
Rheumatology (Oxford, England)|January 13, 2022
Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohortAngeles S Galindo-Feria, Begum Horuluoglu, Jessica Day, et al.
Neuromuscular Disorders : NMD|June 18, 2019
Concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody with reducing body myopathy: Possible double troubleJantima Tanboon, Oranee Sanmaneechai, Sirirat Charuvanij, et al.
Rheumatology (Oxford, England)|June 4, 2024
Anti-FHL1 autoantibodies in adult patients with myositis: a longitudinal follow-up analysisAngeles S Galindo-Feria, Karin Lodin, Begum Horuluoglu, et al.
Clinical & Developmental Immunology|October 27, 2011
Polymerized-type I collagen induces upregulation of Foxp3-expressing CD4 regulatory T cells and downregulation of IL-17-producing CD4⁺ T cells (Th17) cells in collagen-induced arthritisJanette Furuzawa-Carballeda, Perla Macip-Rodríguez, Angeles S Galindo-Feria, et al.
Arthritis Research & Therapy|March 3, 2022
Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndromeAntonella Notarnicola, Charlotta Preger, Susanna L Lundström, et al.
Arthritis Research & Therapy|December 2, 2024
Correction: Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndromeAntonella Notarnicola, Charlotta Preger, Susanna L Lundström, et al.
Pageof 2